Staphylococcus saccharolyticus associated with prosthetic joint infections: clinical features and genomic characteristics.
|Title||Staphylococcus saccharolyticus associated with prosthetic joint infections: clinical features and genomic characteristics.|
|Publication Type||Journal Article|
|Year of Publication||2021|
|Authors||Söderquist, B, Afshar, M, Poehlein, A, Brüggemann, H|
|Date Published||2021 Mar 26|
The anaerobic coagulase-negative staphylococcal species is a member of the normal skin microbiota. However, is rarely found in clinical specimens and its pathogenic potential is unclear. The clinical data of prosthetic hip (n = 5) and shoulder (n = 2) joint implant-associated infections where was detected in periprosthetic tissue specimens are described. The prosthetic hip joint infection cases presented as "aseptic" loosening and may represent chronic, insidious, low-grade prosthetic joint infections (PJIs), eventually resulting in loosening of prosthetic components. All cases were subjected to one-stage revision surgery and the long-term outcome was good. The shoulder joint infections had an acute onset. Polymicrobial growth, in all cases with , was found in 4/7 patients. All but one case were treated with long-term administration of beta-lactam antibiotics. Whole-genome sequencing (WGS) of the isolates was performed and potential virulence traits were identified. WGS could distinguish two phylogenetic clades (clades 1 and 2), which likely represent distinct subspecies of . Little strain individuality was observed among strains from the same clade. Strains of clade 2 were exclusively associated with hip PJIs, whereas clade 1 strains originated from shoulder PJIs. It is possible that strains of the two clades colonize different skin habitats. In conclusion, has the potential to cause PJIs that were previously regarded as aseptic loosening of prosthetic joint devices.
|Grant List||OLL- 334 595951 / / Nyckelfonden at Örebro University Hospital (OLL- 334 595951) and the Fabrikant Vilhelm Pedersen og Hustrus Legat (on the recommendation of the 335 Novo Nordisk Foundation). /|